Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for HIV, viral hepatitis, COVID-19, and cancer. Its commercial portfolio exceeds 25 approved therapies. Key HIV products include Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo; liver disease products include Epclusa for the treatment of chronic HCV infection across all genotypes. The company operates in more than 35 countries and is headquartered in Foster City, California.
Gilead's medicines emphasize first-in-class mechanisms, improved efficacy, convenient single-tablet or infrequent-dosing regimens, and enhanced resistance profiles. Certain products, including Symtuza, are commercialized through collaboration arrangements with partners such as Janssen, with Gilead receiving a revenue share for contributed components.
US 71% · Europe 17% · Rest Of World 12%
geographic · FY2025 (ended Dec 2025) · share of tagged segment revenue (10-K XBRL, as filed)